

Media Release

Zug, 3 April 2023

Ad hoc announcement pursuant to Art. 53 LR

## **HBM Healthcare Investments publishes net asset value per share of CHF 254.80 as at 31 March 2023**

HBM Healthcare Investments closed the fourth quarter of the 2022/2023 financial year ended on 31 March with a small increase in value. The net asset value per share (NAV) increased by 0.5 percent to CHF 254.80. The share price rose by 6.5 percent to CHF 214.00.

### **High level of cash and cash equivalents allows continuation of cash distribution policy**

For the 2022/2023 financial year, the NAV decreased by 7.4 per cent. The private companies (incl. funds) recorded a positive development overall and increased the NAV by 1.6 percent. The listed companies and the other components of the portfolio (incl. costs) reduced the net asset value by 7.7 and 1.3 percent respectively.

Based on the reported NAV as at 31 March, HBM Healthcare Investments expects a net loss of CHF 146 million for the financial year 2022/2023.

The balanced portfolio and the high level of cash and cash equivalents of CHF 232 million allow for the repayment of the CHF 50 million bond due in July from cash on hand as well as the continuation of the company's investment activities and distribution policy.

The figures presented are the preliminary and unaudited results based on the current status of the closing process. The final annual result will be published on Friday, 12 May 2023.

### **Contact**

For further information, please contact Dr. Andreas Wicki on +41 41 710 75 77, or at [andreas.wicki@hbmhealthcare.com](mailto:andreas.wicki@hbmhealthcare.com)

### **About HBM Healthcare Investments**

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

**HBM Healthcare Investments Ltd.**

Bundesplatz 1 CH-6300 Zug | Phone: +41 41 710 75 77 | [info@hbmhealthcare.com](mailto:info@hbmhealthcare.com) | [www.hbmhealthcare.com](http://www.hbmhealthcare.com)

Follow us on Twitter: [@HbmHealthcare](https://twitter.com/HbmHealthcare)

## **Disclaimer**

The publication is for information purposes only and does not constitute an offer to sell or a solicitation to buy or subscribe for securities. This news release does not constitute a prospectus within the meaning of Art. 35ff FinSA, or securities prospectus in the sense of the German securities prospectus law. This news release and the information contained therein is not intended for distribution to the United States of America (USA) or within the USA and may not be distributed or forwarded to US persons (including legal persons) or to publications with a general distribution in the USA. This news release is not an offer or solicitation to buy securities in the United States. HBM Healthcare Investments AG's securities were not issued in accordance with the U.S. U.S. securities laws, and may not be sold, offered for sale, or delivered in the U.S. or to U.S. individuals without prior registration or without a registration exemption. Some information quoted was obtained from external sources HBM considers to be reliable. HBM cannot guarantee the adequacy, accuracy, timeliness or completeness of or be held responsible or liable for errors of fact regarding such data and information obtained from third parties, and this data may change with market conditions.